Navigation Links
Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
Date:4/14/2008

BETHESDA, Md., April 14 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, presented data at the annual meeting of the American Association for Cancer Research (AACR) in San Diego, CA, showing good bioavailability and predictable serum levels of subcutaneously administered BiTE(R) antibodies(1). BiTE antibodies are designed to direct the body's cytotoxic, or cell-destroying, T cells against tumor cells, and represent a new therapeutic approach to cancer therapy.

Micromet conducted a pharmacokinetic study in non-human primates exploring different routes of administration of its BiTE antibody MT110, which is targeting EpCAM (CD326) and is the most advanced BiTE antibody with potential application for the treatment of solid tumors. Continuous intravenous administration, as currently used in an ongoing phase 1 clinical trial with MT103 (MEDI-538), was compared to subcutaneous administration by daily repeated bolus injection and continuous administration using mini-pumps, which are commercially available and routinely used by patients with diabetes for the delivery of insulin. Both subcutaneous regimens resulted in bioavailability of MT110 of 30 to 40 percent, with constant serum trough levels over the six-day treatment period.

"Our pre-clinical results are paving the way for the development of alternative routes of administration for MT110 and other BiTE antibodies to further enhance the quality of life of patients under treatment," comments Patrick A. Baeuerle, Micromet's chief scientific officer. "A very convenient mini-pump system, designed for life-long use by diabetes patients for ins
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Micromet Announces Changes in Management Team
2. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
3. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
4. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
5. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
6. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
7. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
8. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
9. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
10. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
11. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 22, 2015  The U.S. Food and Drug ... the first biosimilar product approved in ... growth in the contract manufacturing organization (CMO) industry, ... is geared to the production of small-molecular drugs ... products. The healthcare market research publisher,s report, ...
(Date:5/22/2015)... 20, 2015 Research and Markets( http://www.researchandmarkets.com/research/28m7nx/guide_to_prepare ... "Guide to Prepare Application Dossiers for Oversea Medical ... " report to their offering. ... segment market of the most growth potentiality, which ... manufacturers and producers to penetrate such market. It ...
(Date:5/22/2015)... 22, 2015 Richmond Pharmacology ... unit with a worldwide reputation for excellence in ... publications in peer reviewed medical journals. Its officers ... regulators in discussions about rules for transparency and ... (Logo: http://photos.prnewswire.com/prnh/20150522/745125) , Clinical research is ...
Breaking Medicine Technology:Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 4China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 2China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 3
... - Arrowhead,Research Corporation (NASDAQ:ARWR) announced today that,majority-owned ... Proceedings of the National Academy of Sciences,(PNAS) ... use multiple,systemic dosing with Calando's lead siRNA ... technologies in targeted,polymeric delivery systems and siRNA ...
... in Two Most Common Mutations, CRANBURY, N.J., ... biopharmaceutical company developing small,molecule, orally-administered pharmacological chaperones ... genetic diseases, announced today,that it will present ... tartrate, AT2101) for Gaucher disease at,the of ...
Cached Medicine Technology:Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on,Targeted, Systemic Delivery of siRNA 2Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on,Targeted, Systemic Delivery of siRNA 3Amicus Therapeutics Presents Preclinical Data from Studies of,Plicera for Gaucher Disease 2Amicus Therapeutics Presents Preclinical Data from Studies of,Plicera for Gaucher Disease 3
(Date:5/22/2015)... 2015 Mountain Point Medical Center, a campus ... ceremony on Friday, May 29, 2015 at 11 a.m., followed ... The new medical center, set to officially open on June ... UT 84043. , “The opening of Mountain Point Medical ... Utah County community,” said Kent Loosle, CEO of Mountain Point ...
(Date:5/22/2015)... 2015 Combination therapy, or polytherapy, ... chronic obstructive pulmonary disorder (COPD) as the dominant ... plc as well as Germany’s Boehringer Ingelheim compete ... But will market payers, clinicians and patients be ... to completely new ones? , In spite of ...
(Date:5/22/2015)... Coordinating care for people with ... providers have not been reimbursed or rewarded for ... Medicare has paved the way by offering reimbursement ... launch of Oculus Health , an innovative ... the platform will now be able to easily ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 ... Health IT solutions, announced today that Bill Lane, ... is the developer of BlueEHS,a first of its ... offers a customizable Electronic Health Records (EHR) with ... interfaces, a telemedicine-enabled comprehensive patient portal, and more. ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 sweetFrog Enterprises, LLC. ... in Jacksonville, Texas. Jacksonville is now the 16th sweetFrog store ... chain was listed as #22 on the Inc. 500 list ... have lived and worked in East Texas for 20 years ... Anderson, owner of the Jacksonville, and nearby Palestine, sweetFrog locations. ...
Breaking Medicine News(10 mins):Health News:Mountain Point Medical Center, a Campus of Jordan Valley Medical Center, Hosts Ribbon Cutting Ceremony and Community Celebration on Friday, May 29, 2015 2Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2Health News:Oculus Health Care Coordination Platform Officially Launched 2Health News:Oculus Health Care Coordination Platform Officially Launched 3Health News:Oculus Health Care Coordination Platform Officially Launched 4Health News:ZH Healthcare Adds Bill Lane to Advisory Board 2Health News:sweetFrog Opens New Location in Jacksonville, Texas 2
... prevention or delay of full-blown disease seen in treated ... Among patients who show early signs of multiple sclerosis, ... halve the risk that they will develop full-blown disease, ... who are diagnosed with multiple sclerosis first show signs ...
... With the thermometer dropping and the onset of flu ... and the public to encourage them to get a seasonal ... supported healthy behaviors and prevention efforts," said Merri Dee, AARP ... protect themselves and those around them by getting vaccinated." , ...
... $30 billion and $34 billion reside in the asbestos ... to pay claims brought by workers who contracted asbestos-related ... Asbestos Litigation Conference" produced in San Francisco by HB ... state court judges from around the country who shared ...
... WASHINGTON, Pa., Oct. 6 RAM Technologies, Inc., ... for health plans, has once again been named ... Tech Employers in the Greater Philadelphia region. ... edge applications that automate the administration of health ...
... While little is known about the causes of glioma, ... this rare but often deadly form of brain cancer ... height. "Our findings suggest that biological factors ... play a role in glioma etiology. This clue could ...
... ... 2009 News Briefs are designed to keep you up-to-date on embargoed studies ... Society of Plastic Surgeons (ASPS) held October 23-27 in Seattle. All briefs ... advance copy of study abstracts, for media registration, or to arrange interviews ...
Cached Medicine News:Health News:Early Drug Treatment May Cut Multiple Sclerosis Risk 2Health News:AARP Encourages All Adults 50+ to Get Flu Vaccine This Season 2Health News:Asbestos Trusts, Asbestos Judges Featured at Two HB Events Dec. 2 & 3 2Health News:RAM Technologies Named to Philadelphia Business Journal's List of Top Tech Employers 2Health News:Physical activity in adolescence associated with decreased risk of brain cancer in adulthood 2Health News:Physical activity in adolescence associated with decreased risk of brain cancer in adulthood 3Health News:Plastic Surgery 2009 News Briefs - Select Research to be Presented on Sunday, October 25 2Health News:Plastic Surgery 2009 News Briefs - Select Research to be Presented on Sunday, October 25 3Health News:Plastic Surgery 2009 News Briefs - Select Research to be Presented on Sunday, October 25 4Health News:Plastic Surgery 2009 News Briefs - Select Research to be Presented on Sunday, October 25 5Health News:Plastic Surgery 2009 News Briefs - Select Research to be Presented on Sunday, October 25 6
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: